If the efficiency is similar, is the price difference between the product a reason to go for stunnox and not the other?
Yes, I think stunnox having the same efficiacy as a Botox / or other highly used botulinum toxin, and if stunnox is priced at a discount, that will be one of the reasons to go for that.
1 Like
Gufic Bio -
Q3 results and concall highlights -
Revenues - 202 vs 177 cr, up 13 pc
EBITDA - 37 vs 34 cr ( margins @ 18 vs 19 pc )
PAT - 22 vs 20 cr
New launches -
Cavim ( Ceftazidine Avibactum - used against bacterial infections ) - receiving encouraging response
First company to launch dual chamber bags of Merofic ( used in severe bacterial infections )
First company to launch Dalbavancin Injection
( used against acute skin infections ) in India
Company maintained market leadership in 2 of its products - Polyfic ( Polymyxin - used against Urinary track bacterial infections ) and Micafung ( anti fungal injections )
Company’s Botuulinum Toxin brand - Zarbot
( used in chronic Migraine’s treatment ) is gaining good acceptance among neurologists in India
Have launched Guficin - to address recurrent implantation failures in the treatment of infertility. Early feedback indicates encouraging results
Sparsh division ( basically selling 90 + injectable molecules directly to 1000 + hospitals ) - has added 70 new hospitals each month in Q3
Indore Capex - progressing well. Capacity to have capacity to make 52 million lyophilised injections and 60 million liquid ampoule injections and 30 million liquid vial injections. This will be the world’s largest single site injectable facility
Segment wise sales -
Domestic formulations( 56 pc of total sales ) - Mainly led by critical care ( 38 pc of domestic sales ), 27 pc of domestic sales come from infertility division, rest comes from mass marketed products, cosmetic brands, Sparsh division
Critical care grew by 16 pc in Q3
Fertility division grew by 18 pc in Q3
Mass marketed products grew by 14 pc in Q3
International formulations( 18 pc of total sales )
Contract manufacturing( 23 pc of sales )
APIs ( 3 pc of sales )
R&D spends for next two years expected to be at around 9-10 pc of sales as the company commercialises new products from its Indore facility
Expect to commercialise the Indore facility by Q1 FY 25. Early plan is to shift a part of domestic business from Navsari facilities to Indore to de-bottleneck the Navsari facilities wrt International orders. By end of FY 25, expect capacity utilisation from Indore at around 25 odd pc as the facility will only be catering to domestic mkts. As they get global approvals in FY 26,27 - capacity utilisation is likely to improve rapidly
Have raised Rs 100 cr from Motilal Oswal MF via preferential allotment ( in Q3 FY 24 )
Already have backlog of orders from Brazil, Germany, Canada. The shifting of domestic production from Navsari to Indore should help company to meet these orders
Disc: holding, biased, not SEBI registered
5 Likes
Wrote a blog on Gufic
Disc - holding and SEBI registered
2 Likes
Hi All,
In the Q3 Concal FY24, the Arisia center was discussed extensively where they would offer anti aging treatments (368 products/services) for all parts of the body including vaginal rejuvenation and also vaginal tightening and mentioned that the costing is from INR 5,000 to INR 15,00,000. They have mentioned that they are close to break even + 10% and would mimic this model at a national level. Would large number of people pay such a price for this segment to be significant for the company? The company mentions the number of footfalls are increasing atleast 10% month on month but what would be scale they can hit.
VPers, please share your thoughts.
Disclosure : only tracking, not invested
1 Like
So Arisia can be a very interesting segment. It was started to create awareness of their botox segment. I was the one who had asked about it on last concall. He had earlier guided to open more centres with a franchise model, but only once his first centre unit economics stabilise.
Skin clinics are a super tough business to run, look at Kaya for eg. He is smart to have not opened more centres until profitability is achieved. But if they do things right, manage to open multiple centres, this could reach upto maybe 5-10% of revenues in the long run, consider it to be optionality for now
Disclosure- invested, recommended, one of my largest positions
5 Likes
So according to your assessment, what are the main growth drivers?
Stunnox
Immuno-therapy
increased capacity of lyophilization
domestic formulations